Begins Coverage on Karyopharm Therapeutics Inc. (KPTI)
Several other equities research analysts also recently weighed in on KPTI. Zacks Investment Research downgraded Karyopharm Therapeutics from a buy rating to a hold rating in a research report on Tuesday, July 18th. BidaskClub downgraded Karyopharm Therapeutics from a sell rating to a strong sell rating in a research report on Monday, July 31st. Canaccord Genuity set a $18.00 price target on Karyopharm Therapeutics and gave the stock a buy rating in a research report on Tuesday, August 8th. Jefferies Group LLC reaffirmed a buy rating and set a $19.00 price target (up from $16.00) on shares of Karyopharm Therapeutics in a research report on Thursday, August 10th. Finally, ValuEngine downgraded Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Friday, August 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. Karyopharm Therapeutics currently has an average rating of Buy and a consensus price target of $17.33.
Karyopharm Therapeutics (KPTI) opened at $11.47 on Wednesday. Karyopharm Therapeutics has a 12-month low of $7.48 and a 12-month high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. equities analysts forecast that Karyopharm Therapeutics will post -2.58 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Begins Coverage on Karyopharm Therapeutics Inc. (KPTI)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/19/begins-coverage-on-karyopharm-therapeutics-inc-kpti.html.
In related news, SVP Christopher Brett Primiano sold 4,958 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total value of $55,777.50. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Mansoor Raza Mirza sold 2,882 shares of the firm’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00. Following the completion of the transaction, the director now directly owns 2,882 shares in the company, valued at $31,702. The disclosure for this sale can be found here. Insiders sold a total of 15,653 shares of company stock worth $174,728 over the last ninety days. 14.71% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in KPTI. Vanguard Group Inc. lifted its stake in Karyopharm Therapeutics by 31.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after purchasing an additional 384,658 shares in the last quarter. Teachers Advisors LLC lifted its stake in Karyopharm Therapeutics by 915.0% in the 1st quarter. Teachers Advisors LLC now owns 420,563 shares of the company’s stock worth $5,400,000 after purchasing an additional 379,127 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Karyopharm Therapeutics by 753.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock worth $3,342,000 after purchasing an additional 271,208 shares in the last quarter. Candriam Luxembourg S.C.A. lifted its stake in Karyopharm Therapeutics by 154.7% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 438,000 shares of the company’s stock worth $3,964,000 after purchasing an additional 266,000 shares in the last quarter. Finally, Tekla Capital Management LLC lifted its stake in Karyopharm Therapeutics by 25.0% in the 2nd quarter. Tekla Capital Management LLC now owns 756,679 shares of the company’s stock worth $6,848,000 after purchasing an additional 151,455 shares in the last quarter. 59.23% of the stock is currently owned by institutional investors and hedge funds.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.